months 23 accelerate to 48 pounds monthly as your dose stabilizes
Dose reduction or discontinuation may be necessary if you develop: Persistent, intolerable gastrointestinal symptoms despite supportive measures Acute pancreatitis (discontinue permanently) Severe hypoglycemia, particularly if taking concurrent insulin or sulfonylureas Acute kidney injury or worsening renal function Gallbladder disease symptoms (abdominal pain, jaundice) Diabetic retinopathy complications (particularly with semaglutide) Severe hypersensitivity reactions including anaphylaxis or angioedema Pregnancy or plans for pregnancy (for semaglutide, discontinue at least two months before planned conception
Full criteria are set out in NICE TA875
Thyroid tumours (in animals): In rats, these drugs caused rare thyroid tumours
Cheng CK, Luo JY, Lau CW, Cho WC, Ng CF, Ma RCW, Tian XY, Huang Y
Throughout the year, the AAPCC recorded 3,316 calls related to semaglutide This figure is more than double the previous years calls and represents a 15-fold increase since 2019, CNN reported